Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883123 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
A Phase 4 study of Open Angle Glaucoma, sponsored by Prairie Eye Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06883123 is a Phase 4 study of Open Angle Glaucoma that is actively recruiting participants, run by Prairie Eye Center. The registered enrollment target is 70 participants, below the 332-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06883123, a Phase 4 study of Open Angle Glaucoma, is actively recruiting participants, sponsored by Prairie Eye Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.
Conditions Studied
Interventions
- DRUG Latanoprost 0.005% Ophthalmic Solution
- DRUG Simbrinza 0.2%-1% Ophthalmic Suspension
- DRUG Rocklatan 0.02%-0.005% Ophthalmic Solution
- DRUG Cosopt PF 2%-0.5% Ophthalmic Solution
Study Locations (1)
Illinois
- Prairie Eye Center - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06883123
The ClinicalTrials.gov registry entry for NCT06883123 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (79% lower). The listed sponsor is Prairie Eye Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 4 interventions - of which Latanoprost 0.005% Ophthalmic Solution is the first listed.
NCT06883123 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06883123 about?
NCT06883123 is a clinical study titled "Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost". A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.
What is the current status of trial NCT06883123?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2025-05-14. Estimated completion is 2026-04-01.
What conditions does trial NCT06883123 study?
This clinical trial studies the following conditions: Open Angle Glaucoma.
What interventions are being tested in trial NCT06883123?
The interventions under investigation include: Latanoprost 0.005% Ophthalmic Solution (DRUG), Simbrinza 0.2%-1% Ophthalmic Suspension (DRUG), Rocklatan 0.02%-0.005% Ophthalmic Solution (DRUG), Cosopt PF 2%-0.5% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT06883123?
This trial is sponsored by Prairie Eye Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883123 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.